Previous 10 | Next 10 |
HAMPTON, N.J., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing symptom control and quality of life measurements from the Phase 1b study of CDX-0159 in patients with antihistamine refractory cold contact urticaria (ColdU...
HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers. CDX-0159 is a humanized monoclonal antibody that specifical...
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded at a new 52-week high today of $52.57. This new high was reached on approximately average trading volume as 523,000 shares traded hands, while the average 30-day volume is approximately 593,000 shares. Celldex Therapeutics Inc is a...
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at $50.69, eclipsing its 52-week high. Approximately 523,000 shares have changed hands today, as compared to an average 30-day volume of 695,000 shares. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused o...
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded at a new 52-week high today of $50.10. So far today approximately 523,000 shares have been exchanged, as compared to an average 30-day volume of 842,000 shares. In the past 52 weeks, shares of Celldex Therapeutics Inc. have traded ...
Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at $50.01, eclipsing its 52-week high. Approximately 523,000 shares have changed hands today, as compared to an average 30-day volume of 938,000 shares. Celldex Therapeutics Inc is a biopharmaceutical company. It is focused o...
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at a new 52-week high of $49.07. So far today approximately 523,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. There is potential upside of 24.0% for shares of Celldex Therapeutics Inc. b...
Celldex (NASDAQ:CLDX): Q2 GAAP EPS of -$0.34 beats by $0.06. Revenue of $3.5M (+1358.3% Y/Y) beats by $2.86M. Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2021, along with the approximately $270.0 million in net proceeds raised in ...
- Positive data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria presented at EAACI 2021 - - Raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021 - HAMPTON, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celldex Th...
Celldex Therapeutics Inc. (NASDAQ:CLDX) traded today at a new 52-week high of $47.63. This new high was reached on below average trading volume as 523,000 shares traded hands, while the average 30-day volume is approximately 1.3 million shares. There is potential upside of 10.6% for shar...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...